Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 23, 2016
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen & Co. 36th Annual Health Care Conference on March 8, in Boston. Dan Brennan, executive vice president and chief...
Feb 23, 2016FDA-Approved ACUITY™ X4 Quadripolar Left Ventricular Leads to be used in Trial Pursuing MRI Labeling for Cardiac Defibrillation and Resynchronization SystemsBoston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the ACUITY™ X4 Quadripolar Left Ventricular (LV) leads. The FDA approval of the quadripolar leads,...
Feb 22, 2016First polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe; IMPERIAL trial initiated to seek regulatory approvals in U.S. and AsiaBoston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing commercialization immediately in the European Union and...
-
Feb 8, 2016CMS will cover percutaneous LAAC therapy for Medicare beneficiaries consistent with the FDA label when specific conditions are met
Boston Scientific Corporation (NYSE: BSX) announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial appendage closure (LAAC) therapy under specific...
- Feb 4, 2016
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.978 billion during the fourth quarter ended December 31, 2015. This represents 10 percent operational revenue growth (constant...
